India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

The drug is indicated for the treatment of alopecia areata - a condition in which the immune system attacks hair follicles, ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...

Shares of Sun Pharmaceutical Industries climbed nearly 3 per cent on Tuesday after the firm said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for ...

As part of the agreement, Incyte has granted Sun Pharma a limited, non-exclusive license to US Patent Nos. 9,662,335 and ...

"The launch of LEQSELVI in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," said Richard Ascroft, CEO, ...

Mumbai: Sun Pharmaceutical Industries Limited has announced the launch of LEQSELVI (deuruxolitinib) 8 mg tablets in the U.S.

The delay in Sun Pharma's launch of Leqselvi in the US was caused by a patent infringement case, which was later settled in a ...